Drug Trial Radar · NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
325
Planned (sponsor's estimate)
Start
Jul 23, 2025
Primary completion
Dec 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and change in disease activity of surzetoclax in adult participants with relapsed/refractory (R/R) MM. Adverse events and change in disease activity will be assessed. Surzetoclax is an investigational drug being developed for the treatment of R/R MM. In Substudy 1 there will be dose escalation and dose expansion phases where participants will receive various doses (escalation) or 1 of 2 doses (expansion) of surzetoclax in combination with daratumumab + dexamethasone, to determine the best dose of surzetoclax. In Substudy 2, there will be a dose escalation phase where participants will receive various doses of surzetoclax alone. In Substudy 3 there will be dose escalation and optimization phases where participants will receive various doses (escalation) or 1 of 2 doses (optimization) of of surzetoclax and etentamig to determine the best dose of surzetoclax and etentamig. Optimization will also include etentamig received alone. Approximately 325 adult participants with R/R MM will be enrolled in the study in approximately 55 sites worldwide. In Substudy 1 escalation phase, participants will receive oral surzetoclax tablets in combination with subcutaneous (SC) daratumumab injections + oral dexamethasone tablets and in the expansion phase, will receive 1 of 2 doses oral surzetoclax tablets in combination with SC daratumumab injections + oral dexamethasone tablets or daratumumab injections + oral pomalidomide + oral dexamethasone tablets. In Substudy 2, Japanese participants will receive oral surzetoclax tablets. In Substudy 3 escalation phase, participants will receive oral surzetoclax tablets in combination with IV etentamig and in the expansion phase, will receive 1 of 2 doses of both oral surzetoclax tablets in combination with of IV etentamig, or IV etentamig alone. The total study duration is approximately 4.5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution. The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.
Conditions
- Multiple Myeloma
Interventions
SurzetoclaxDrug
Oral
DaratumumabDrug
Subcutaneous (SC) Injection
DexamethasoneDrug
Oral
PomalidomideDrug
Oral
EtentamigDrug
Intravenous Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicities (DLT)s of ABBV-453Time frame: Up to Approximately 45 Months
- Number of Participants with Adverse Events (AE)sTime frame: Up to Approximately 4.5 Years
Locations
51 sites in 12 countries. Site status is shown where the registry gives one.
University of Southern California /ID# 272414
Los Angeles, California · Recruiting
Yale University School of Medicine /ID# 272447
New Haven, Connecticut · Recruiting
Dana-Farber Cancer Institute /ID# 271846
Boston, Massachusetts · Recruiting
University of Michigan Health System - Ann Arbor /ID# 271536
Ann Arbor, Michigan · Recruiting
Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 271214
New York, New York · Recruiting
Atrium Health Levine Cancer Institute /ID# 271510
Charlotte, North Carolina · Recruiting
University Of North Carolina Health Care - Hillsborough Campus /ID# 272454
Hillsborough, North Carolina · Recruiting
Atrium Health Wake Forest Baptist Medical Center /ID# 271294
Winston-Salem, North Carolina · Recruiting
Oregon Health and Science University /ID# 272282
Portland, Oregon · Recruiting
University of Texas - Southwestern Medical Center /ID# 271914
Dallas, Texas · Recruiting
Huntsman Cancer Institute /ID# 271618
Salt Lake City, Utah · Recruiting
Northwest Medical Specialties Tacoma /ID# 272506
Tacoma, Washington · Recruiting
Liverpool Hospital /ID# 272002
Liverpool, New South Wales, Australia · Recruiting
Calvary Mater Newcastle /ID# 272498
Waratah, New South Wales, Australia · Recruiting
St Vincent's Hospital - Melbourne /ID# 271997
Fitzroy, Victoria, Australia · Recruiting
Epworth HealthCare /ID# 272497
Richmond, Victoria, Australia · Recruiting
CHU de Liege /ID# 271430
Liège, Belgium · Recruiting
UZ Gent /ID# 271432
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Universitair Ziekenhuis Leuven /ID# 272382
Leuven, Vlaams-Brabant, Belgium · Recruiting
CHU de Montpellier - Hopital Saint Eloi /ID# 275570
Montpellier, Herault, France · Recruiting
Hopital Universitaire Necker Enfants Malades /ID# 275571
Paris, Île-de-France Region, France · Recruiting
Centre Hospitalier Universitaire de Poitiers /ID# 275563
Poitiers, New Aquitaine, France · Recruiting
IUCT Oncopole /ID# 275568
Toulouse, Occitanie, France · Recruiting
Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 275562
Nantes, Pays de la Loire Region, France · Recruiting
Universitaetsklinikum Hamburg-Eppendorf /ID# 275803
Hamburg, Germany · Recruiting
Universitaetsklinikum Heidelberg /ID# 275598
Heidelberg, Baden-Wurttemberg, Germany · Recruiting
Klinikum der Universitaet Muenchen Grosshadern /ID# 276658
Munich, Bavaria, Germany · Recruiting
Universitaetsklinikum Wuerzburg /ID# 276657
Würzburg, Bavaria, Germany · Recruiting
Rambam Health Care Campus- Haifa /ID# 271256
Haifa, Israel · Recruiting
Hadassah Medical Center-Hebrew University /ID# 271253
Jerusalem, Israel · Recruiting
Rabin Medical Center. /ID# 272073
Petah Tikva, Central District, Israel · Recruiting
The Chaim Sheba Medical Center /ID# 271251
Ramat Gan, Tel Aviv, Israel · Recruiting
Tel Aviv Sourasky Medical Center /ID# 271252
Tel Aviv, Tel Aviv, Israel · Recruiting
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 276306
Milan, Italy · Recruiting
The Jikei University Hospital /ID# 272091
Tokyo, Japan · Recruiting
Nagoya City University Hospital /ID# 271427
Nagoya, Aichi-ken, Japan · Recruiting
University Hospital Kyoto Prefectural University of Medicine /ID# 271911
Kyoto, Kyoto, Japan · Recruiting
The University of Osaka Hospital /ID# 271636
Suita-shi, Osaka, Japan · Recruiting
Japanese Red Cross Medical Center /ID# 272018
Shibuya-ku, Tokyo, Japan · Recruiting
Uniwersytecki Szpital Kliniczny w Poznaniu - Szamarzewskiego /ID# 276237
Poznan, Greater Poland Voivodeship, Poland · Recruiting
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.